Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Advances in Cardiorenal Syndrome: 2nd Edition
share announcement

New Advances in Cardiorenal Syndrome: 2nd Edition

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 15 June 2025 | Viewed by 5060

Special Issue Editor

Dr. Rainer Ullrich Pliquett

E-Mail Website
Guest Editor
1. Dept Internal Med II, Martin Luther UniversityHalle Wittenberg, 06108 Halle, Germany
2. Dept Nephrol and Diabetol, Carl Thiem Hospital, 03048 Cottbus, Germany
Interests: cardiology; heart failure; hypertension; diabetes mellitus; chronic heart failure; blood pressure; atherosclerosis; chronic kidney disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

As the Guest Editor, it is my privilege to invite you to discover new and relevant research results on cardiorenal syndrome in the upcoming second edition of our Special Issue titled “Advances in Cardiorenal Syndrome” (https://www.mdpi.com/journal/jcm/special_issues/Advances_Cardiorenal_Syndrome). The new collection will cover the “renal factor” in cardiorenal syndrome that has become more relevant to both nephrologists and cardiologists. In addition, the prevention of renal replacement therapies via the optimization of medical therapy is the focus. Since the conception of this Special Issue, sodium-glucose-cotransporter-2 inhibitors have demonstrated a huge potential as cardiorenal medication in order to delay the onset of renal replacement therapies. Other upcoming medications, including finerenone, may add value as cardiorenal medications as well. Last, the pathogenesis of uremic cardiomyopathy, a new disease entity for heart failure during acute or chronic kidney failure is being reviewed in the upcoming Special Issue.

We are glad to have you here to follow up on these and other upcoming publications. Authors should feel free to submit their work. The diagnostics of and therapies for cardiorenal syndrome are topics of interest. We believe that this second edition will be an essential addition to the collective knowledge in the field.

Dr. Rainer Ullrich Pliquett
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiorenal syndrome
  • outcome
  • hyperkalemia
  • acute kidney injury
  • chronic kidney disease
  • chronic heart failure

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1431 KiB  
Article
Venous Excess Ultrasound Score Is Associated with Worsening Renal Function and Reduced Natriuretic Response in Patients with Acute Heart Failure
by Sofya Sovetova, Kristina Charaya, Tamerlan Erdniev, Dmitry Shchekochikhin, Alexandra Bogdanova, Sergey Panov, Natalya Plaksina, Elmira Mutalieva, Natalia Ananicheva, Viktor Fomin and Denis Andreev
J. Clin. Med. 2024, 13(20), 6272; https://doi.org/10.3390/jcm13206272 - 21 Oct 2024
Cited by 2 | Viewed by 2388
Abstract
Background: The venous excess ultrasound score (VExUS) is used to objectify systemic venous congestion. The aim of the paper was to determine the association between VExUS grades and worsening renal function (WRF), reduced natriuretic response, diuretics resistance, and mortality in patients with acute [...] Read more.
Background: The venous excess ultrasound score (VExUS) is used to objectify systemic venous congestion. The aim of the paper was to determine the association between VExUS grades and worsening renal function (WRF), reduced natriuretic response, diuretics resistance, and mortality in patients with acute heart failure (AHF). Methods: One hundred patients were included, and Doppler ultrasound of hepatic, portal, and renal veins was performed. Severity of congestion was graded using the VExUS score (grade 0, 1, 2, or 3). Sodium concentration in a spot urine sample was assessed in 2 h after the first loop diuretic administration and was adjusted for the prescribed dose of furosemide (31 mmol/40 mg). Diuretics resistance was defined as the need to double the starting dose of intravenous furosemide in 6 h. Results: Patients with VExUS grade 3 showed a higher incidence of WRF (OR: 11.17; 95% CI: 3.86–32.29; p < 0.001) and a decreased natriuretic response: a spot urine sodium content of <50 mmol/L (OR: 21.53; 95% CI: 5.32–87.06; p < 0.001) and an adjusted spot urine sodium content of <31 mmol/40 mg (OR: 9.05; 95% CI: 3.15–25.96; p < 0.001). The risk of diuretic resistance (OR: 15.31; 95% CI: 5.05–46.43; p < 0.001), as well as the need for inotropic and/or vasopressor support (OR: 11.82; 95% CI: 3.59–38.92; p < 0.001), was higher in patients with severe congestion. The hospital mortality rate increased in patients with VExUS grade 3 compared to in patients with other grades (OR: 26.4; 95% CI: 5.29–131.55; p < 0.001). Conclusions: Patients with AHF and VExUS grade 3 showed a higher risk of developing WRF, a decreased diuretic and natriuretic response, a need for inotropic and/or vasopressor support, and a poor prognosis during their hospital stay. Full article
(This article belongs to the Special Issue New Advances in Cardiorenal Syndrome: 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 815 KiB  
Review
Acute Kidney Injury During Sepsis and Prognostic Role of Coexistent Chronic Heart Failure
by Jens Soukup and Rainer U. Pliquett
J. Clin. Med. 2025, 14(3), 964; https://doi.org/10.3390/jcm14030964 - 3 Feb 2025
Viewed by 1207
Abstract
Background: The recently updated definition of sepsis considers pathophysiologic mechanisms to guide initial therapy. Clearly, generalized recommendations for sepsis therapy may be limited by pre-existing multimorbidity in addition to sepsis-related multi-organ failure. In particular, a recommendation regarding fluid rescue therapy may require adequate [...] Read more.
Background: The recently updated definition of sepsis considers pathophysiologic mechanisms to guide initial therapy. Clearly, generalized recommendations for sepsis therapy may be limited by pre-existing multimorbidity in addition to sepsis-related multi-organ failure. In particular, a recommendation regarding fluid rescue therapy may require adequate cardiac function and/or the absence of sepsis-induced cardiomyopathy. In all sepsis patients with compromised cardiac function or sepsis-induced cardiomyopathy, a patient-specific therapy regimen is required to prevent pulmonary edema and early death. Similarly, in sepsis, acute kidney injury with or without pre-existing chronic kidney disease requires attention to be paid to excretory renal function to avoid hypervolemia-mediated acute heart failure. In addition, hyponatremia related to intravascular hypovolemia may be explained by vasopressin stimulation. However, hypothetically, vasopressin hyporesponsiveness may contribute to sepsis-related acute kidney injury. In this review, relevant cardiorenal pathomechanisms will be assessed in the context of sepsis therapy. Conclusions: In conclusion, therapy for sepsis with acute kidney injury has to take cardiac comorbidity, if present, into account. The extent to which vasopressin hyporesponsiveness aggravates sepsis-mediated hypovolemia and renal insufficiency should remain a subject of further study. Full article
(This article belongs to the Special Issue New Advances in Cardiorenal Syndrome: 2nd Edition)
►▼ Show Figures

Figure 1

13 pages, 258 KiB  
Review
Sodium-Glucose-Cotransporter-2 Inhibitor Therapy and Intermitted Fasting in Cardiorenal Syndrome: The Role of Glucose-Mediated Oxidative Stress
by Katrin Schröder
J. Clin. Med. 2025, 14(3), 746; https://doi.org/10.3390/jcm14030746 - 24 Jan 2025
Cited by 1 | Viewed by 970
Abstract
Cardiorenal syndrome (CRS) is a complex clinical disorder characterized by the interplay between heart and kidney dysfunction. This condition is exacerbated by comorbidities such as diabetes mellitus, which contribute to glucose-mediated oxidative stress, further complicating the management of CRS. The management of CRS [...] Read more.
Cardiorenal syndrome (CRS) is a complex clinical disorder characterized by the interplay between heart and kidney dysfunction. This condition is exacerbated by comorbidities such as diabetes mellitus, which contribute to glucose-mediated oxidative stress, further complicating the management of CRS. The management of CRS has evolved with the discovery of sodium-glucose-cotransporter-2 (SGLT2) inhibitors, which have been established as effective agents in reducing hyperglycemia and demonstrated cardiorenal protective effects. Concurrently, intermittent fasting has gained attention as an intervention without pharmacological treatment for its metabolic benefits, including improved glucose metabolism and insulin regulation and sensitivity, both with a potential reduction in oxidative stress. This review provides a summary of current findings on the roles of SGLT2 inhibitors and intermittent fasting in managing CRS, with a particular focus on glucose-mediated oxidative stress. We evaluate the mechanisms by which these interventions exert their effects, identify gaps in current research, and offer recommendations for future studies. While both SGLT2 inhibitors and intermittent fasting demonstrate potential in managing CRS, more research is needed to elucidate their long-term efficacy, safety, and potential synergistic effects. Full article
(This article belongs to the Special Issue New Advances in Cardiorenal Syndrome: 2nd Edition)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop